B7-H1 antigen

AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells
Ganggang Zhang, Bin Lan, Xin Zhang, Mengyao Lin, Yi Liu, Junsong Chen, Fang Guo

Journal for ImmunoTherapy of Cancer May 2023, 11 (5) e006483; DOI: 10.1136/jitc-2022-006483
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers
Zheng-Zheng Yu, Yun-Ya Liu, Wei Zhu, Ding Xiao, Wei Huang, Shan-Shan Lu, Hong Yi, Ting Zeng, Xue-Ping Feng, Li Yuan, Jie-Ya Qiu, Di Wu, Qi Wen, Jian-Hua Zhou, Wei Zhuang, Zhi-Qiang Xiao

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006345; DOI: 10.1136/jitc-2022-006345
Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
Xiaozhen Zhang, Mengyi Lao, Jian Xu, Yi Duan, Hanshen Yang, Muchun Li, Honggang Ying, Lihong He, Kang Sun, Chengxiang Guo, Wen Chen, Haitao Jiang, Xiaoyu Zhang, Xueli Bai, Tingbo Liang

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003982; DOI: 10.1136/jitc-2021-003982
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
Valerie Glutsch, Patrick Schummer, Hermann Kneitz, Anja Gesierich, Matthias Goebeler, Detlef Klein, Christian Posch, Christoffer Gebhardt, Sebastian Haferkamp, Lisa Zimmer, Jürgen C Becker, Ulrike Leiter, Michael Weichenthal, Dirk Schadendorf, Selma Ugurel, Bastian Schilling

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005930; DOI: 10.1136/jitc-2022-005930
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
Elisa Baldelli, K Alex Hodge, Guido Bellezza, Neil J Shah, Guido Gambara, Angelo Sidoni, Martina Mandarano, Chamodya Ruhunusiri, Bryant Dunetz, Maysa Abu-Khalaf, Julia Wulfkuhle, Rosa I Gallagher, Lance Liotta, Johann de Bono, Niven Mehra, Ruth Riisnaes, Antonella Ravaggi, Franco Odicino, Maria Isabella Sereni, Matthew Blackburn, Angela Zupa, Giuseppina Improta, Perry Demsko, Lucio Crino', Vienna Ludovini, Giuseppe Giaccone, Emanuel F Petricoin, Mariaelena Pierobon

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002179; DOI: 10.1136/jitc-2020-002179
Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
Shunichi Taki, Kohei Matsuoka, Yuko Nishinaga, Kazuomi Takahashi, Hirotoshi Yasui, Chiaki Koike, Misae Shimizu, Mitsuo Sato, Kazuhide Sato

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (11) e003036; DOI: 10.1136/jitc-2021-003036
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
Qi-Hua Peng, Chun-Hua Wang, Hong-Min Chen, Rong-Xin Zhang, Zhi-Zhong Pan, Zhen-Hai Lu, Gao-Yuan Wang, Xin Yue, Wenlin Huang, Ran-Yi Liu

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001638; DOI: 10.1136/jitc-2020-001638
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Rachel E Sanborn, Omid Hamid, Elisabeth GE de Vries, Patrick A Ott, Javier Garcia-Corbacho, Valentina Boni, Johanna Bendell, Karen A Autio, Daniel C Cho, Ruth Plummer, Mark Stroh, Lawrence Lu, Fiona Thistlethwaite

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002446; DOI: 10.1136/jitc-2021-002446
CX-072 (pacmilimab), a Probody^® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Aung Naing, Fiona Thistlethwaite, Elisabeth G.E. De Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Patrick A. Ott, Patricia LoRusso, Javier Garcia-Corbacho, Valentina Boni, Johanna Bendell, Karen A. Autio, Manreet Randhawa, Greg Durm, Marta Gil-Martin, Mark Stroh, Alison L. Hannah, Hendrik-Tobias Arkenau, Alexander Spira

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002447; DOI: 10.1136/jitc-2021-002447
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Chushu Li, Hao Chi, Shouyan Deng, Ke Xu, Huanbin Wang, Han Yao, Yungang Wang, Dawei Chen, Xun Guo, Jing-Yuan Fang, Fang He, Jie Xu

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002443; DOI: 10.1136/jitc-2021-002443

Main menu

B7-H1 antigen

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

B7-H1 antigen

Pages